Get notified when COCH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRemoved Risk Disclosures
- Material Weakness (removed) — Material weaknesses in internal controls (insufficient accounting personnel, deficient risk assessment, inadequate IT controls, missing formal policies) disclosed in baseline filing but entire controls section absent from current filing.
revenue $39,000, net income -$4.4M. Envoy completes 56-patient trial enrollment, material weakness disclosures vanish
Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 1, 2025 · ~2 min read
Key Changes
-
high
All 56 pivotal trial patients enrolled and activated by March 2025; first three reached 12-month follow-up milestone. FDA approval now expected H2 2027 (no panel) or H1 2028 (with panel).
MD&A: Clinical Progress verify on EDGAR → -
high
February 2026 equity raise brought in $27.6M net proceeds, boosting cash from $3.7M to $25.3M. Management projects runway into Q2 2027, extendable via warrant exercises.
MD&A: Liquidity verify on EDGAR → -
high
Term Loans ($25M outstanding in Q1 2025) extinguished August 2025, eliminating $495K quarterly interest expense and removing related-party debt obligation.
MD&A: Debt Extinguishment verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (EPM 10-K) is open in full — no account needed.
Partner
Trade COCH commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify